2010
Federal Schedule I status remains the legal baseline
Ibogaine remained listed in Schedule I under the federal Controlled Substances Act, a status reflected in the DEA controlled-substances schedule.
2010—2026 · public record
Policy Timeline
A chronological guide to Rick Perry’s public ibogaine advocacy, Texas policy activity, federal research actions, and the legal and safety context that remains important alongside them.
READ THE RECORD
IN CATEGORIES.
This timeline separates research activity from advocacy and from binding policy. That distinction matters: a public endorsement is not a clinical finding, and an executive action or appropriation is not the same thing as a change in federal controlled-substance status.
01 / 2010–2018
Background before the advocacy push
Ibogaine’s legal position and the accumulated safety literature form the baseline for later political discussion. The dates below mark regulatory and research context rather than actions by Rick Perry.
2012–2018
Safety concerns remain central to published discussion
Clinical and observational literature continued to describe potential cardiac and other risks associated with ibogaine exposure; the ibogaine reference overview also notes its controlled status and reported safety concerns.
02 / 2019–2023
Public advocacy enters the policy conversation
Rick Perry became a visible advocate for additional ibogaine research, especially in relation to veterans and traumatic brain injury. These were advocacy and policy-positioning actions, not a change in law or an FDA approval.
2019
Perry publicly promotes investigation of ibogaine
Public accounts of Perry’s involvement describe his support for pursuing research into ibogaine and related compounds in veteran-health discussions. For broader background on the people and institutions shaping this debate, see the site’s map of political actors and public advocates.
2020–2023
Organizational advocacy takes a more visible role
Americans for Ibogaine became part of the public campaign associated with expanding research attention. Perry’s statements and organizational advocacy should be read separately from clinical results; a football-focused ibogaine discussion illustrates how public narratives can extend beyond policy into sport and personal testimony.
2023
FDA research pathway remains distinct from approval
The FDA’s investigational new drug application framework describes how sponsors may seek to begin clinical investigation; an IND milestone is a research step, not approval for routine treatment.
03 / 2024–2025
Texas funding and research-facing activity
State support can direct resources toward a defined study or research program. It does not independently reschedule ibogaine federally or settle the clinical questions that research is meant to examine.
State action
Texas policy discussions elevated the possibility of state-supported research involving ibogaine for veterans. The relevant policy question is the scope and conditions of any appropriation, not a presumption that state attention changes federal restrictions.
Research action
Where studies proceed, their protocol, oversight, participant protections, and published results matter more than promotional language. The site’s safety and evidence guide explains why evidence, adverse-event reporting, and legal limits must remain part of the same conversation.
Advocacy around ibogaine often overlaps with opioid-use-disorder conversations, but the terms are not interchangeable. Accounts centered on ibogaine and methadone describe a particularly sensitive area where individual experiences should not be treated as a substitute for supervised research or medical advice.
Similarly, public interest in treatment outside the United States may lead readers to material about ibogaine beyond Mexico. Geographic location does not erase the need to assess legal status, medical risk, study quality, and the difference between a commercial claim and a regulated clinical program.
04 / 2026
Federal action: what an executive order can and cannot do
Federal directives can prioritize reviews, coordination, or research-related action. Their wording, implementing agencies, and subsequent legal or regulatory steps determine their actual effect.
2026
Executive-order discussion places ibogaine in a federal policy frame
The 2026 executive-order milestone belongs in the record as federal policy activity. It should be assessed against the order’s text and implementation rather than treated as an automatic rescheduling or approval event; the Federal Register’s executive-order archive is the appropriate official record for presidential documents.
2026
FDA IND milestones remain research milestones
Any announced IND-related progress should be described narrowly: it concerns the ability to investigate under a specified protocol. It does not establish a product’s safety or effectiveness for routine use.
Discussion of public figures may also draw on athlete or combat-sport stories. Material about boxers discussing ibogaine and MMA-related ibogaine narratives can be useful for understanding public interest, but personal testimony is not equivalent to a clinical result or a policy finding.
For a broader orientation to the site’s evidence-first approach, return to the main ibogaine policy overview. The distinction between emerging research, individual reports, political statements, and binding rules is the central discipline of this timeline.
“A timeline can show what happened without deciding what the evidence will ultimately show.” Policy reading principle
05 / FAQ
The legal and evidence line
Does advocacy change ibogaine’s legal status?
No. Public advocacy, organizational activity, and research announcements do not themselves alter federal scheduling. Ibogaine remains a Schedule I controlled substance under federal law unless legal status changes through the applicable process.
Does an FDA IND mean ibogaine is approved treatment?
No. An investigational new drug application can allow a specified clinical investigation to proceed; it is not FDA approval for routine medical use. The difference is especially important when claims move faster than published evidence.
What belongs on a policy timeline?
A useful timeline distinguishes public statements, advocacy actions, research milestones, state appropriations, federal directives, safety findings, and binding legal changes. Mosaic Prairie’s approach to sourcing and uncertainty explains why those categories should not be blended.
Policy attention is not a substitute for evidence.
Ibogaine’s public profile may change through advocacy, funding decisions, and federal action. Its legal status, safety questions, and research findings still require precise reading.
Review safety and evidence context →